Trial Profile
BI 201335 + peginterferon alfa-2a + ribavirin (P/R) in P/R non-responders with chronic genotype 1 hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2015
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary) ; Peginterferon; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SILEN-C2
- 19 Apr 2012 Results have been presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL-2012) according to a Boehringer Ingelheim media release.
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
- 05 Nov 2010 New trial record.